GeoVax Labs, Inc. — Q1 2019 Form 10-Q
Business context and reporting period
GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies using its MVA-VLP platform. Its programs target HIV, Zika, hemorrhagic fever viruses, malaria, chronic hepatitis B, and cancers. The company reported unaudited results for the three months ended March 31, 2019; the comparable period is Q1 2018. It has not generated product sales revenue and does not expect product revenue for at least several years.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / prior date |
|---|---|---|
| Grant and collaboration revenue | $364,232 | $221,299 |
| Research and development expense | $555,718 | $486,994 |
| General and administrative expense | $510,064 | $357,228 |
| Operating loss | $(701,550) | $(622,923) |
| Net loss | $(701,454) | $(621,813) |
| Net loss per common share | $(1.43) | $(2.50) |
| Cash used in operating activities | $(317,361) | $(381,573) |
| Cash and cash equivalents | $175,985 | $259,701 at Dec. 31, 2018 |
| Working capital | $(1,196,467) | $(1,005,127) at Dec. 31, 2018 |
| Total liabilities | $1,679,793 | $1,664,411 at Dec. 31, 2018 |
Revenue increased about 65% year over year, mainly reflecting grant activity. R&D expense rose about 14% and G&A expense about 43%; management attributed the G&A increase mainly to investment banking arrangements, investor relations, and travel. Net loss widened about 13%. Loss per share and share counts reflect the filing’s retroactive presentation for the one-for-500 reverse stock split effective April 30, 2019.
Cash declined by $83,716 during the quarter. Financing activities provided $237,917, including $240,000 net proceeds from Series G preferred stock; operating activities used $317,361. The company had $47,917 remaining principal on its GRA note payable at March 31, 2019. Current liabilities included $1,360,337 of deferred management salaries and directors’ fees. The filing reports no committed credit line.
Material changes, outlook, and risks
- Management said existing cash, government funding and committed equity funding were expected to support planned operations only into the third quarter of 2019. The filing states that substantial doubt exists about GeoVax’s ability to continue as a going concern beyond that point; management’s plans do not alleviate that doubt. Further capital may not be available on favorable terms, or at all.
- GeoVax had $2,525,419 in approved grant funds available for use in 2019 and 2020. Approximately $1,247,273 was expected to reimburse third-party services. Outstanding vendor and subcontractor purchase commitments were approximately $487,000, expected to be reimbursed under existing grants.
- The Series G financing provided for up to $1.0 million gross proceeds in multiple closings. The first closing included $250,000 cash plus cancellation of $250,000 of term notes; a second $250,000 closing occurred on April 26, 2019. A further closing of up to $250,000 remained available. Preferred stock conversion terms and associated warrants include price-adjustment provisions that may result in dilution.
- The company expected NIAID-funded HIV vaccine trial HVTN 132 to begin enrolling patients in mid-2019, and expected an AGT-conducted Phase 1 trial using combined technologies in the second half of 2019. These are expectations, not reported outcomes.
- The April 30, 2019 one-for-500 reverse split was intended to improve marketability and support financing or possible Nasdaq listing requirements; the filing cautions there is no assurance minimum price requirements will be met. On May 13, 2019, 610,089 common shares were reported issued and outstanding.
- Management warned that vaccine development, regulatory approval, competition, and access to additional capital are uncertain. R&D spending may fluctuate, and programs may be delayed or discontinued. There were no material changes to previously disclosed risk factors, no legal proceedings, and no material changes to internal control over financial reporting reported.
Most important facts for investors to verify
- Whether GeoVax secured financing sufficient to fund operations beyond the third quarter of 2019 and addressed the stated going-concern uncertainty.
- Actual cash burn, grant reimbursements, and availability and timing of the $2.525 million in approved grant funds.
- Payment or continued deferral of the $1.36 million in management and director compensation, and the effect on liquidity.
- Completion and terms of the Series G closings, conversions, warrant exercises, and resulting dilution; compare share counts after the reverse split.
- Whether planned clinical trials began and produced meaningful progress, and whether any product candidates advanced toward regulatory approval or commercialization.